News Center

Company news

Media reports

16

2021-07

Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay

Suzhou, July 16, 2021 - Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that Paraguay’s Ministry of Public Health and Social Welfare (MSPBS) has granted an emergency use authorization (EUA) for proxalutamide to treat hospitalized patients with COVID-19 infections at the MSPBS hospitals.

Picture Name

15

2021-07

Kintor Pharmaceutical Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for Treatment of COVID-19 in India and Africa

Suzhou, July 15, 2021-- Kintor Pharmaceutical Limited (HKEX:9939) today announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd. ("Fosun Pharma Development"), on the commercialisation of proxalutamide for the treatment of COVID-19 indication in India and 28 African countries (the"Collaboration Regions"). Kintor and Fosun Pharma Development will collaborate on the development, promotion, and sales of proxalutamide for the treatment of COVID-19 indication.

Picture Name

13

2021-07

Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne

Suzhou, July 13, 2021 - Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small-molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for its novel drug GT20029 for treating androgenetic alopecia (AGA) and acne subjects. GT20029 is the first topical Proteolysis Targeting Chimera (PROTAC) compound globally which has entered the clinical stage. Following China Center for Drug Evaluation (CDE) 's IND approval for GT20029's clinical study in April 2021, the clinical study in the US is about to start.

Picture Name

11

2021-07

Kintor Pharmaceutical Announced U.S. FDA Has Greenlighted Phase II Clinical Trial for Pyrilutamide to Treat Androgenetic Alopecia

Suzhou, July 11, 2021 - Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted pyrilutamide (KX-826)’s phase II clinical trial for the treatment of androgenetic alopecia (AGA).

Picture Name

06

2021-07

Kintor: Q2 2021 Business Update at a Glance

Kintor: Q2 2021 Business Update at a Glance

Picture Name

15

2021-06

Proxalutamide's Pivotal Study of Treating COVID-19 Male Outpatients Sponsored by Kintor was Approved by ANVISA and CONEP in Brazil

Suzhou, June 15, 2021 - Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved the phase III clinical trial of proxalutamide to treat male patients with mild or moderate COVID-19 symptoms on June 11, 2021[1].

Picture Name
< 1...141516...25 > proceed page

Kintor